Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CombAct-HIB
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
CombAct-HIB is a pediatric combined vaccine developed by Sanofi Pasteur. It provides active immunization against diphtheria, tetanus, pertussis, Haemophilus influenzae type b, and poliomyelitis. The vaccine contains diphtheria anatoxin, tetanus anatoxin, whole inactivated pertussis, Haemophilus influenzae type b conjugated to tetanus anatoxin, and whole inactivated trivalent poliovirus. It is administered intramuscularly.
- Brand names
- CombAct-HIB
02
Targets
PV3 (Sabin) (Poliovirus type 3 antigen)TT (Tetanus toxoid)
Beyond the preview
Go deeper on CombAct-HIB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CombAct-HIB.